research JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.
Search
for
Sort by
Research
90-120 / 1000+ results
research Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study
Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
research Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.
research Janus Kinase Inhibitors against Other Biological Treatments in Alopecia Areata
Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.
research Low serum biotin in Japanese children fed with hydrolysate formula
Japanese infants fed hydrolysate formula may have low biotin levels.
research Identification of a novel heterozygous mutation in the first Japanese case of Marie Unna hereditary hypotrichosis
Researchers found a new genetic mutation causing a rare hair loss condition in the first Japanese child studied.
research Lentivirus‐mediated subcutaneous JAM‐A modification promotes skin wound healing in a mouse model by strengthening the secretory function and proliferation of fibroblasts
JAM-A modification speeds up skin wound healing by boosting fibroblast growth.
research Dietary Habits in Japanese Patients with Alopecia Areata
Japanese patients with alopecia areata often have a higher BMI and consume more vitamin C, fruit, and retinol, which may affect their condition's development or severity.
research 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.
research A study of normal eyelashes in Japanese individuals
Japanese females generally have longer, denser, and curlier eyelashes than males.
research Janus kinase inhibitors for alopecia areata: a review of clinical data
JAK inhibitors effectively and safely treat alopecia areata with few serious side effects.
research A review of Janus kinase inhibitor use in scarring alopecia
Janus kinase inhibitors are promising for treating scarring alopecia, but more research is needed for safety and personalized treatments.
research FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
The FDA approved a new Pfizer drug for hair loss in teens.
research The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients
JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.
research Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
Blocking Janus kinase 1 helps stop inflammation and regrow hair, making it a good treatment for hair loss from alopecia areata.
research At the crossroads of 2 alopecias: Androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors
JAK inhibitors help hair regrowth but not fully effective for androgenetic alopecia.
research [JAK INHIBITORS FOR THE TREATMENT OF ALOPECIA AREATA].
JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.
research Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review
Biologics and JAK inhibitors may improve treatment for scarring alopecias.
research Evaluating dermatologists’ knowledge of and attitudes toward Janus kinase inhibitor therapy for the treatment of alopecia areata
Dermatologists are hesitant to prescribe Janus kinase inhibitors for alopecia areata due to safety concerns and lack of knowledge.
research Real-world experience quantifying access to JAK inhibitor care for alopecia areata patients: a patient-centered survey study
Access to JAK inhibitor therapy for alopecia areata patients is difficult, especially for racial minorities.
research Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
research 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
research Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
JAK inhibitors for alopecia areata have different safety risks, requiring specific monitoring for each drug.
research Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
Deuruxolitinib effectively regrows hair in adults with alopecia areata and is well tolerated.
research Short-term malignancy risk of JAK inhibitors in severe alopecia areata: a multicenter cohort study
JAK inhibitors do not increase cancer risk in severe alopecia areata compared to traditional treatments.
research Switching JAK inhibitors: evaluating baricitinib’s effectiveness in alopecia areata after tofacitinib failure
Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.
research Efficacy and safety of JAK inhibitors in treating lichen planopilaris or frontal fibrosing alopecia
JAK inhibitors may effectively treat lichen planopilaris and frontal fibrosing alopecia with minimal side effects.
research JAK inhibition decreases the autoimmune burden in Down syndrome
JAK inhibition reduces autoimmune issues in Down syndrome.
research Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata
Ritlecitinib is an effective new treatment for Alopecia Areata.
research 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.